| 產(chǎn)品編號(hào) | bs-4500R |
| 英文名稱(chēng) | BRLF1 Rabbit pAb |
| 中文名稱(chēng) | EBV立即早期基因BRLF1抗體 |
| 別 名 | Human herpesvirus 4 type 2 |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 細(xì)菌及病毒 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human (predicted: HHV4 tp2) |
| 產(chǎn)品應(yīng)用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 67 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from HHV4tp2 BRLF1: 151-250/605 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
No data available. Epstein-Barr病毒(EB V)是皰疹病毒科γ亞科成員,是一種在人群中分布廣泛的感染因子,在全世界90%以上人感染此病毒。E BV可引起人類(lèi)的傳染性單核細(xì)胞增多癥,還與Burkitt’s淋巴瘤及鼻咽癌的發(fā)生密切相關(guān)。EB V的基因組長(zhǎng)約172kb,基因組的末端有多個(gè)長(zhǎng)約0.5kb的末端重復(fù)序列,可以使病毒基因組環(huán)化成環(huán)狀游離體(episom e),并以此形式持續(xù)存在于受感染細(xì)胞的細(xì)胞核內(nèi)。EB V有潛伏周期和裂解周期兩種狀態(tài)。E BV進(jìn)入細(xì)胞后,通常很快進(jìn)入潛伏期,病毒基因組持續(xù)存在于細(xì)胞內(nèi)。但病毒在受感染細(xì)胞的少數(shù)細(xì)胞中可以進(jìn)入增殖期,并產(chǎn)生病毒顆粒。佛波酯、鈣離子載體、丁酸鹽、抗膜免疫球蛋白處理潛伏有EB V的B淋巴細(xì)胞,都可以誘導(dǎo)E BV由潛伏狀態(tài)轉(zhuǎn)換到裂解狀態(tài)。BZLF1(Bam H I片段Z左向第一讀碼框)和BRLF1(Bam H I片段R左向第一讀碼框)兩個(gè)基因在病毒的潛伏周期轉(zhuǎn)變?yōu)榱呀庵芷诘倪^(guò)程中起重要作用。 |
| 產(chǎn)品圖片 |
Tissue/cell: human colon carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-BRLF1 Polyclonal Antibody, Unconjugated(bs-4500R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
